

## INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2009

(Rs. In Lacs)					
Sr.No	Particulars	Quarter ended 31.3.2009 (Unaudited)	Quarter ended 31.3.2008 (Unaudited)	Year ended 31.3.2009 (Unaudited)	Year ended 31.03.2008 (Nine Months)* (Audited)
1	<b>(a) Sales and Income from Operations</b>	8,580	8,920	35,526	27,189
	Less : Excise Duty	81	212	424	921
	<b>Net Sales and Income from Operations</b>	8,499	8,708	35,102	26,268
	<b>(b) Other Operating income</b>	142	70	338	225
	<b>Total</b>	8,641	8,778	35,440	26,493
2	<b>Expenditure :</b>				
	(a) (Increase)/Decrease in Finished Goods Stock in trade and work in progress	344	75	(513)	(295)
	(b) Consumption of raw materials	2,921	2,712	12,416	8,819
	(c) Purchase of traded goods	490	1,019	3,094	2,749
	(d) Employees cost	1,298	1,127	4,822	3,227
	(e) Depreciation	300	267	1,116	778
	(f) Research & Development Expenses	234	269	916	718
	(g) Other Expenditure	2,542	2,539	9,755	6,774
	(h) Total	8,129	8,008	31,606	22,770
3	<b>Profit from Operations before Interest and Exceptional Items</b>	512	770	3,834	3,723
4	Other Income	1	2	55	25
5	<b>Profit before Interest and Exceptional Items</b>	513	772	3,889	3,748
6	Interest	129	137	585	361
7	<b>Profit after Interest but before Exceptional Items</b>	384	635	3,304	3,387
8	Exceptional Items	-	-	-	-
9	<b>Profit from Ordinary Activities before tax</b>	384	635	3,304	3,387
10	Provision for Tax - Current	48	50	369	355
	- Deferred	(20)	19	110	123
	- Fringe Benefit Tax	12	28	93	72
	- Prior Year	-	-	(31)	-
	- MAT Credit	(48)	(355)	(369)	(355)
11	<b>Net Profit from Ordinary Activities after tax</b>	392	893	3,132	3,192
12	Extraordinary Items	-	162	-	182
13	<b>Net Profit for the period</b>	392	731	3,132	3,010
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	24,196
16	<b>Earning Per Share (EPS) - Not Annualised - Rs.</b>				
	(a) Basic and diluted EPS before Extraordinary Items	3.19	7.27	25.49	25.98
	(b) Basic and diluted EPS after Extraordinary Items	3.19	5.95	25.49	24.50
17	Public shareholding				
	- No of Shares	50,29,231	48,82,016	50,29,231	48,82,016
	- % of Shareholding	40.93	39.73	40.93	39.73
18	Promoters and promoters group shareholding				
	<b>a) Pledged/Encumbered</b>				
	- Number of shares	8,200	-	8,200	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.11	-	0.11	-
	- Percentage of shares (as a % of the total share capital of the company)	0.07	-	0.07	-
	<b>b) Non-encumbered</b>				
	- Number of shares	7249283	-	7249283	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.89	-	99.89	-
	- Percentage of shares (as a % of the total share capital of the company)	59	-	59	-

Notes :

- 1\* In view of the decision to change the accounting year of the company from July-June to April-March, the Financial Year for 2007-08 is for 9 months period from 1st July 2007 to 31st March 2008.
- 2 During the third quarter of current financial year 2008-09, the Board of Directors declared an interim dividend of Rs.3.25 per share. The said interim dividend has been paid to the shareholders.
- 3 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- 4 The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- 5 Summary of investor complaints:As on 01.1.2009:Nil, Received during quarter :16, Resolved:16, Pending as on 31.3.2009:Nil.
- 6 The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 29th April 2009 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai  
Date : April 29, 2009

**Suresh G. Kare**  
Chairman & Managing Director